"Extrafine single inhaler triple therapy effect on health status, lung function and adherence in COPD patients: A Panhellenic prospective non-interventional study - The TRIBUNE study".

[1]  W. Pohl,et al.  TRICOP - A Real-world effectiveness study with a single-inhaler extrafine triple therapy over 52 weeks in Austrian patients with COPD. , 2021, Respiratory medicine.

[2]  Kevin McCarthy,et al.  Standardization of Spirometry 2019 Update. An Official American Thoracic Society and European Respiratory Society Technical Statement , 2019, American journal of respiratory and critical care medicine.

[3]  N. Papadopoulos,et al.  The importance of real-life research in respiratory medicine: manifesto of the Respiratory Effectiveness Group , 2019, European Respiratory Journal.

[4]  R. Stanford,et al.  Medication adherence and persistence in chronic obstructive pulmonary disease patients receiving triple therapy in a USA commercially insured population , 2019, International journal of chronic obstructive pulmonary disease.

[5]  Kelly H Zou,et al.  Real world data: an opportunity to supplement existing evidence for the use of long-established medicines in health care decision making , 2018, Journal of multidisciplinary healthcare.

[6]  N. Roche,et al.  Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial , 2018, The Lancet.

[7]  Mario Cazzola,et al.  Adherence to COPD treatment: Myth and reality. , 2017, Respiratory medicine.

[8]  Dave Singh,et al.  Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial , 2017, The Lancet.

[9]  Dave Singh,et al.  Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial , 2016, The Lancet.

[10]  P. Jones,et al.  The COPD Assessment Test: What Do We Know So Far?: A Systematic Review and Meta-Analysis About Clinical Outcomes Prediction and Classification of Patients Into GOLD Stages. , 2016, Chest.

[11]  D. Price,et al.  The inevitable drift to triple therapy in COPD: an analysis of prescribing pathways in the UK , 2015, International journal of chronic obstructive pulmonary disease.

[12]  B. Cosío,et al.  Validation of the ‘Test of the Adherence to Inhalers’ (TAI) for Asthma and COPD Patients , 2016, Journal of aerosol medicine and pulmonary drug delivery.

[13]  S. Kon,et al.  Minimum clinically important difference for the COPD Assessment Test: a prospective analysis. , 2014, The Lancet. Respiratory medicine.

[14]  D. Elbourne,et al.  Systematic review of the Hawthorne effect: New concepts are needed to study research participation effects☆ , 2014, Journal of clinical epidemiology.

[15]  P. Jones,et al.  Development and first validation of the COPD Assessment Test , 2009, European Respiratory Journal.

[16]  J. Bourbeau,et al.  Patient adherence in COPD , 2008, Thorax.

[17]  M. Pistolesi,et al.  Outcomes for COPD pharmacological trials: from lung function to biomarkers , 2008, European Respiratory Journal.

[18]  D. Mannino,et al.  Global burden of COPD: risk factors, prevalence, and future trends , 2007, The Lancet.

[19]  S. Spencer,et al.  Impact of preventing exacerbations on deterioration of health status in COPD , 2004, European Respiratory Journal.